Aurobindo Pharma Limited’s Board of Directors has approved the re-appointment of Mr. Mangalam Ramasubramanian Kumar as a Non-executive and Independent Director. This second term of five years will commence on April 1, 2027, following the completion of his current term on March 31, 2027. The decision is based on the recommendation of the Nomination and Remuneration Committee and is subject to shareholder approval via a postal ballot.
Board Approves Director Re-appointment
Aurobindo Pharma Limited announced today, November 4, 2026, that its Board of Directors has approved the re-appointment of Mr. Mangalam Ramasubramanian Kumar as a Non-executive and Independent Director. This decision follows a recommendation from the Nomination and Remuneration Committee.
Details of Re-appointment
Mr. Kumar will serve for a second term of five years, commencing from April 1, 2027. His current tenure as a Non-executive and Independent Director concludes on March 31, 2027. The re-appointment is subject to the approval of the Company’s members through a postal ballot, as per regulatory requirements.
Director Profile and Independence
Mr. Mangalam Ramasubramanian Kumar (DIN 03628755) is a science graduate from the University of Madras with extensive experience, including serving as Chairman of LIC of India from March 2019 to March 2023. He is not related to any Director or Key Managerial Personnel of Aurobindo Pharma. The company affirms that Mr. Kumar is not debarred from holding a director’s office by any SEBI order or other authority.
Board Meeting Concluded
The Board meeting where this decision was made commenced at 4:15 p.m. and concluded at 6:00 p.m. The company has provided detailed information as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in an attached annexure.
Source: BSE
